118 related articles for article (PubMed ID: 38431352)
1. Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
Ederhy S; Cadranel J; Granger C; Hammoudi N
Lancet; 2024 Mar; 403(10429):860-861. PubMed ID: 38431352
[No Abstract] [Full Text] [Related]
2. Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy.
Yamaura T; Suzuki H
J Thorac Oncol; 2018 Oct; 13(10):e209-e210. PubMed ID: 30244857
[No Abstract] [Full Text] [Related]
3. Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
Chen HF; Wang WX; Li XL; Xu CW; Du KQ; Zhu YC; Fang MY
J Thorac Oncol; 2019 Oct; 14(10):e217-e219. PubMed ID: 31558230
[No Abstract] [Full Text] [Related]
4. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.
Zaemes J; Hall RD; Gentzler RD
J Thorac Oncol; 2018 Aug; 13(8):e136-e137. PubMed ID: 30049373
[No Abstract] [Full Text] [Related]
6. Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach.
Grosse A; Grosse C
Cytopathology; 2020 May; 31(3):232-235. PubMed ID: 32072673
[No Abstract] [Full Text] [Related]
7. Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.
Xu Z; Hao X; Lin L; Li J; Xing P
Thorac Cancer; 2021 Aug; 12(16):2233-2240. PubMed ID: 34180588
[TBL] [Abstract][Full Text] [Related]
8. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
[No Abstract] [Full Text] [Related]
9. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
10. Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma.
Chen YY; Lin KH; Kuo YS; Tsai YM; Huang HK; Huang TW
World J Surg Oncol; 2023 Oct; 21(1):326. PubMed ID: 37833769
[TBL] [Abstract][Full Text] [Related]
11. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
12. Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.
Dai Y; Zhong F; Liu W; Song Q; Hu W
J Cancer Res Clin Oncol; 2021 May; 147(5):1379-1388. PubMed ID: 33550434
[TBL] [Abstract][Full Text] [Related]
13. A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.
Kimura H; Amino Y; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
Cancer Commun (Lond); 2019 Nov; 39(1):67. PubMed ID: 31675980
[No Abstract] [Full Text] [Related]
14. Unusual Presentation of Lung Adenocarcinoma With Paraneoplastic Stiff Person Syndrome: Role of EGFR Tyrosine Kinase Inhibitors.
Sarwari N; Galili Y; Perez A; Avgeropoulos N; Tseng J
J Thorac Oncol; 2019 Aug; 14(8):e179-e180. PubMed ID: 31345344
[No Abstract] [Full Text] [Related]
15. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC
PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations].
Li HX; Wang ZZ; Zhang GW; Zhang MN; Zheng XX; Yang JP; Ma ZY; Wang HJ
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):783-791. PubMed ID: 31648503
[No Abstract] [Full Text] [Related]
17. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
18. Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.
Hsia TC; Liang JA; Li CC; Chien CR
Thorac Cancer; 2018 Nov; 9(11):1398-1405. PubMed ID: 30152040
[TBL] [Abstract][Full Text] [Related]
19. Transformation of lung adenocarcinoma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challenging phenomenon.
El Hussein S; Khader SN
Diagn Cytopathol; 2019 Aug; 47(8):845-850. PubMed ID: 31017747
[TBL] [Abstract][Full Text] [Related]
20. Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation.
Lee SH; Kim EY; Kim A; Chang YS
Cancer Biol Ther; 2020 Aug; 21(8):741-748. PubMed ID: 32543264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
